News >

Weber Highlights Potency of Adjuvant Nivolumab in Melanoma

Brandon Scalea
Published: Thursday, Sep 27, 2018

Jeffrey Weber, MD, PhD
Jeffrey Weber, MD, PhD
Nivolumab (Opdivo) demonstrated a sustained efficacy benefit versus ipilimumab (Yervoy) as an adjuvant therapy in patients with high-risk resected stage III/IV melanoma.

in Melanoma, discussed the promise of nivolumab in this setting and a general overview of the melanoma treatment landscape.

OncLive: Please provide some background of the CheckMate-238 trial.

Weber: At the 2018 ASCO Annual Meeting, I reported on the updated results from this large phase III double-blind trial. It had an active control arm. Patients with a high risk of recurrence—50% or higher risk of recurrence beyond 5 years—who also had stage IIIb, IIIc, or IV melanoma, were randomly allocated to either nivolumab, the PD-1 antibody, or ipilimumab, the CTLA-4 antibody.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x